TyraTech, Inc. (AIM: TYR), a natural life sciences company, announces that 3,659,338 common shares in the Company on its restricted "TYR" trading line have now migrated to its unrestricted trading line "TYRU".
Following the migration of these shares, the Company will continue to have a total of 107,776,005 common shares admitted to AIM (excluding those shares admitted and not allotted under the blocklisting announced on 25 February 2011), of which 80,489,636 will continue to trade under the symbol "TYR" in a restricted manner as permitted by Regulation S of the U.S. Securities Act of 1993 (the "Securities Act") and 27,286,369 will trade under the symbol "TYRU" in an unrestricted manner pursuant to an exemption provided under the Securities Act. CREST settlement will not be available for trades in "TYR" shares.
In addition, the Company holds 1,084,413 common shares in treasury.
For further information please contact:
TyraTech Inc.
Alan Reade, Executive Chairman
Tel: +1 919 415 4310
Peter Jerome, Chief Financial Officer
Tel: +1 919 415 4280
N+1 Brewin, Nominated Adviser and Joint Broker
Aubrey Powell / Robert Beenstock / Alex Wright
Tel: +44 20 3201 3170
First Columbus LLP, Joint Broker
Chris Crawford
Tel: +44 20 3002 2070
This web site contains investor-related information which is restricted to non-U.S. persons or Qualified Institutional Buyers as defined in Rule 144A of the U.S. Securities Act of 1933, as amended (the "Securities Act"). The information provided herein is not an offer to buy or sell, or a solicitation of an offer to buy or sell, any TyraTech, Inc. securities. By viewing pages on this web site, you agree and acknowledge that TyraTech, Inc.'s common stock has not been registered under the Securities Act and that you are a non-U.S. person, Qualified Institutional Buyer as defined in Rule 144A of the Securities Act., or you are not holding, acquiring or selling TyraTech, Inc. common stock for the account or benefit of any U.S. person.